MedTrace Logo

Early Detection and IntervenTion in Heart Failure

NCT07731490 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18000

Last updated 2026-07-28

No results posted yet for this study

Summary

Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood test measuring NT-proBNP levels can facilitate the early diagnosis of HF, it is not routinely used in clinical practice.

The aim of this study is to evaluate whether a combined strategy for the early diagnosis and treatment of HF can reduce hospitalizations. This strategy includes:

1. increasing awareness of HF among patients and physicians,
2. using NT-proBNP testing for the early detection of HF in high-risk patients, and
3. promptly initiating guideline-directed HF treatment when the diagnosis is confirmed.

The researchers will assess whether this strategy effectively reduces hospitalizations due to acute heart failure over an 18-month follow-up period.

Conditions

  • Heart Failure (HF)

Interventions

OTHER

Intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis.

The study aims to fill critical gaps and evaluate patient-centred outcomes, including hospitalization for acute HF, and health economic implications by using routine clinical data and the standard operating procedures as part of routine clinical practice in the participating sites.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-03
Primary Completion
2028-04-30
Completion
2030-04-30

Countries

  • Austria
  • Bulgaria
  • Germany
  • Italy
  • Netherlands
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07731490 on ClinicalTrials.gov